TransMedics Group, Inc.
TMDXHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeHeadquartered within the healthcare sector, TransMedics Group, Inc. focuses on Medical Devices services and products. TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. With a market capitalization of $2.56B, it sits in mid-cap territory. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Market Cap
$2.56B
Beta
1.88
P/E (TTM)
16.93
P/E (Fwd)
26.75
EPS (TTM)
$4.37
EPS (Fwd)
$2.77
ROE
45.2%
ROA
5.2%
Cash
$461.7M
Total Debt
$863.4M
Free CF
$108.8M
52W Change
-32.7%
Annual Financials
Cash vs Debt
The company holds $461.7M in cash, though total debt stands at $863.4M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $108.8M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 45.2% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.2% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $93.5M (2022) to $605.5M (2025), reflecting a 548% increase over the period.
TransMedics Group, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for TransMedics Group, Inc. and its sector.